TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

Daily Photo Galleries

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Amazon.com distribution center planned for Pittsburgh’s West End
  2. Smartphone coupons just one way stores aim to increase spontaneous buys
  3. EQT posts $110.9 million profit in latest quarter
  4. IMF cuts U.S., global growth forecasts for ’14
  5. Employers start to feel wage pressures
  6. Gas pipeline issues challenge for producers, users
  7. Wesco posts higher profit, lowers full year outlook
  8. GM profit 2Q falls 85% on recall costs
  9. Latrobe’s Ci Medical Technologies transforms to medical device business
  10. 10 million Americans sought help to enroll in Obamacare
  11. Rising number of health care workers have less than 4-year degree, study shows
Subscribe today! Click here for our subscription offers.